Menu

Concentrix Corporation (CNXC)

$37.62
+0.66 (1.79%)
Get curated updates for this stock by email. We filter for the most important fundamentals-focused developments and send only the key news to your inbox.

Data provided by IEX. Delayed 15 minutes.

Market Cap

$2.4B

Enterprise Value

$6.8B

P/E Ratio

7.5

Div Yield

3.83%

Rev Growth YoY

+35.2%

Rev 3Y CAGR

+19.9%

Earnings YoY

-20.0%

Earnings 3Y CAGR

-14.8%

Company Profile

At a glance

The AI Transformation Thesis: Concentrix has engineered a fundamental business model shift from low-margin transactional work to high-value AI-enabled solutions, with its iX suite of autonomous and agentic AI products on track to become accretive to earnings by Q4 2025. This transition—evidenced by $1 billion in revenue from solutions that didn't exist at scale 24 months ago—positions the company to capture disproportionate value as clients move from AI experimentation to enterprise-wide deployment.

Webhelp Integration as a Strategic Catalyst: The September 2023 acquisition of Webhelp has been fully integrated ahead of schedule, creating a scaled platform that is driving client consolidation wins. The completion of the financial ERP migration by end of 2024 sets the stage for net synergy benefits in 2025 and beyond, providing a structural advantage over smaller competitors struggling to match this global delivery footprint.

Margin Pressure as a Temporary Investment Phase: Q2 and Q3 2025 margin compression—driven by tariff-related client project pauses and strategic capacity holding—represents a deliberate investment in future growth rather than structural deterioration. Management's guidance for sequential margin improvement through 2025, combined with the iX suite's path to accretion, suggests this headwind will reverse as committed volumes migrate and transformation projects ramp.

Price Chart

Loading chart...

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks